Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Income (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Net Income for 10 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 9.73% to -$47.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$196.5 million, a 24.59% increase, with the full-year FY2025 number at -$196.5 million, up 24.58% from a year prior.
  • Net Income was -$47.5 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$52.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$32.3 million in Q2 2024 to a low of -$141.4 million in Q1 2024.
  • A 5-year average of -$50.0 million and a median of -$45.7 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 171.08% in 2024, then soared 64.99% in 2025.
  • Rhythm Pharmaceuticals' Net Income stood at -$50.9 million in 2021, then increased by 16.44% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then dropped by 3.98% to -$43.3 million in 2024, then decreased by 9.73% to -$47.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Net Income are -$47.5 million (Q4 2025), -$52.9 million (Q3 2025), and -$46.6 million (Q2 2025).